Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-207572
Filing Date
2026-05-06
Accepted
2026-05-06 07:30:34
Documents
54
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tcrx-20260331.htm   iXBRL 10-Q 2145505
2 EX-31.1 tcrx-ex31_1.htm EX-31.1 23639
3 EX-31.2 tcrx-ex31_2.htm EX-31.2 23657
4 EX-32.1 tcrx-ex32_1.htm EX-32.1 9864
5 EX-32.2 tcrx-ex32_2.htm EX-32.2 10979
  Complete submission text file 0001193125-26-207572.txt   6701513

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tcrx-20260331.xsd EX-101.SCH 1050512
58 EXTRACTED XBRL INSTANCE DOCUMENT tcrx-20260331_htm.xml XML 729432
Mailing Address 830 WINTER STREET WALTHAM MA 02451
Business Address 830 WINTER STREET WALTHAM MA 02451 857-399-9500
TScan Therapeutics, Inc. (Filer) CIK: 0001783328 (see all company filings)

EIN.: 825282075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40603 | Film No.: 26945823
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)